All In Biotech

Drug Trial Radar · NCT05632939

ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.

A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable Gastric/Esophagogastric Junction Cancer.

Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

62

Actual

Start

Feb 21, 2023

Primary completion

Oct 31, 2025

Study completion Feb 10, 2026

Sponsor

Lead sponsor
AskGene Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
First posted
Dec 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was an open-label, phase 1/2 study to evaluate safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in combination with CAPOX and PD-1 inhibitors in first-line treatment of patients with locally advanced, recurrent, or metastatic gastric and esophagogastric junction adenocarcinoma.

Conditions

  • Gastric Cancer
  • Gastroesophageal Cancer (GC)

Interventions

  • ASKB589 +CAPOX+Sintilimab/TislelizumabDrug

    Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 6 cycles; Capecitabine: oral administration, 1000mg/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Sintilimab/Tislelizumab was administered intravenously at 200mg. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years. ASKB589 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events as assessed by CTCAE v5.0Time frame: up to 21 days following last dose
  2. The incidence and case number of DLT (Dose Limiting Toxicity) during observation period.Time frame: up to 21 days following last dose
  3. Maximum Tolerated Dose (MTD)Time frame: up to 21 days following last dose
  4. The recommended doseTime frame: from date of treatment start until data cut-off, up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.